<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on May 29, 2018</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT01828489</url>
  </required_header>
  <id_info>
    <org_study_id>NOPHO-DBH-AML2012</org_study_id>
    <secondary_id>2012-002934-35</secondary_id>
    <nct_id>NCT01828489</nct_id>
  </id_info>
  <brief_title>Research Study for Treatment of Children and Adolescents With Acute Myeloid Leukaemia 0-18 Years</brief_title>
  <acronym>AML2012</acronym>
  <official_title>NOPHO-DBH AML 2012 Protocol. Research Study for Treatment of Children and Adolescents With Acute Myeloid Leukaemia 0-18 Years</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Vastra Gotaland Region</agency>
      <agency_class>Other</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>Vastra Gotaland Region</source>
  <oversight_info>
    <has_dmc>Yes</has_dmc>
  </oversight_info>
  <brief_summary>
    <textblock>
      This study evaluates the effect of different induction courses in children and adolescents
      with newly diagnosed acute myeloid leukemia. In the first course patients are randomised to
      receive either standard anthracycline therapy with mitoxantrone or experimental DaunoXome. In
      the second course patients are randomised between standard treatment with ADxE (cytarabine,
      DaunoXome, etoposide) or experimental therapy with FLADx (fludarabine, cytarabine,
      DaunoXome).
    </textblock>
  </brief_summary>
  <overall_status>Recruiting</overall_status>
  <start_date>March 2013</start_date>
  <completion_date type="Anticipated">March 2023</completion_date>
  <primary_completion_date type="Anticipated">March 2018</primary_completion_date>
  <phase>Phase 3</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>Randomized</allocation>
    <intervention_model>Factorial Assignment</intervention_model>
    <primary_purpose>Treatment</primary_purpose>
    <masking>None (Open Label)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>Minimal residual disease</measure>
    <time_frame>On day 22 after the first induction and after second induction</time_frame>
    <description>MRD will be measured by flow cytometry. In the randomisation for course 1 the endpoint is at day 22. In the randomisation for course 2 the endpoint is immediately before start of consolidation</description>
  </primary_outcome>
  <secondary_outcome>
    <measure>Event-free survival</measure>
    <time_frame>5 years</time_frame>
    <description>Event-free survival at five years</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Acute toxicity</measure>
    <time_frame>six months</time_frame>
    <description>Hematological and other organ toxicity after each course</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Long-term toxicity</measure>
    <time_frame>10 years</time_frame>
    <description>Long-term toxicity in particular cardiac toxicity</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Overall survival</measure>
    <time_frame>Five years</time_frame>
    <description>Overall survival at five years</description>
  </secondary_outcome>
  <number_of_arms>4</number_of_arms>
  <enrollment type="Anticipated">300</enrollment>
  <condition>Pediatric Acute Myeloblastic Leukemia</condition>
  <arm_group>
    <arm_group_label>Standard arm MEC and ADxE</arm_group_label>
    <arm_group_type>Active Comparator</arm_group_type>
    <description>Standard protocol arm with mitoxantrone in first course (MEC) and standard ADxE treatment in course two</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Experimental DxEC and standard ADxE</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>Experimental arm with DaunoXome in course one (DxEC) and standard ADxE treatment in course two</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Standard arm MEC and experimental FLADx</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>Experimental arm with standard MEC in the first course (MEC) and experimental treatment with FLADx in course two</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Experimental DxEC and experimental FLADx</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>Experimental treatment with DaunoXome in course one (DxEC) and experimental treatment with FLADx in course two</description>
  </arm_group>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Randomisation course 1 mitoxantrone versus DaunoXome</intervention_name>
    <description>In course one with cytarabine and etoposide either mitoxantrone (standard) or DaunoXome (experimental) is given as anthracycline.</description>
    <arm_group_label>Standard arm MEC and ADxE</arm_group_label>
    <arm_group_label>Experimental DxEC and standard ADxE</arm_group_label>
    <arm_group_label>Experimental DxEC and experimental FLADx</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Randomisation course 2 ADxE versus FLADx</intervention_name>
    <description>The second course is randomised to either ADxE (standard arm) or FLADx</description>
    <arm_group_label>Standard arm MEC and ADxE</arm_group_label>
    <arm_group_label>Standard arm MEC and experimental FLADx</arm_group_label>
    <arm_group_label>Experimental DxEC and experimental FLADx</arm_group_label>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:

          1. AML as defined by the WHO diagnostic criteria

          2. Age &lt; 19 years at time of diagnosis

          3. Written informed consent

        Exclusion Criteria:

          1. Previous chemotherapy or radiotherapy. This includes patient with secondary AML after
             previous cancer therapy

          2. AML secondary to previous bone marrow failure syndrome.

          3. Down syndrome (DS)

          4. Acute promyelocytic leukaemia (APL)

          5. Myelodysplastic syndrome (MDS)

          6. Juvenile Myelomonocytic Leukaemia (JMML)

          7. Known intolerance to any of the chemotherapeutic drugs in the protocol.

          8. Fanconi anaemia

          9. Major organ failure precluding administration of planned chemotherapy.

         10. Positive pregnancy test

         11. Lactating female or female of childbearing potential not using adequate contraception
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>N/A</minimum_age>
    <maximum_age>18 Years</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Jonas Abrahamsson, MD, PhD</last_name>
    <role>Study Chair</role>
    <affiliation>Children's Cancer Centre, Queen Silvias Childrens and Adolescents Hospital 416 85 Gothenburg, Sweden</affiliation>
  </overall_official>
  <overall_official>
    <last_name>Barbara de Moerloose, MD, PhD</last_name>
    <role>Principal Investigator</role>
    <affiliation>Ghent University Hospital, Children´s Hospital, Princess Elisabeth, Department of Pediatric Hematology-Oncology, 3K12D, De Pintelaan 185 - 9000 Gent, Belgium</affiliation>
  </overall_official>
  <overall_official>
    <last_name>Ha Shau-Yin, MD, PhD</last_name>
    <role>Principal Investigator</role>
    <affiliation>Dept of Paediatrics &amp; Adolescent Medicine, Queen Mary Hospital, The University of Hong Kong, Pokfulam, Hong Kong</affiliation>
  </overall_official>
  <overall_official>
    <last_name>Henrik Hasle, MD, PhD</last_name>
    <role>Principal Investigator</role>
    <affiliation>Department of Pediatrics, Aarhus University Hospital Skejby 8200 Aarhus N, Denmark</affiliation>
  </overall_official>
  <overall_official>
    <last_name>Kirsi Jahnukainen, MD, PhD</last_name>
    <role>Principal Investigator</role>
    <affiliation>Division of Hematology-Oncology and Stem Cell Transplantation, Children's Hospital, Helsinki University Central Hospital, PL 281, 00029 Helsinki, Finland</affiliation>
  </overall_official>
  <overall_official>
    <last_name>Olafur G Jonsson, MD, PhD</last_name>
    <role>Principal Investigator</role>
    <affiliation>Children´s Hospital, Landspitali University Hospital, Hringbraut, 101 Reykjavik, Iceland</affiliation>
  </overall_official>
  <overall_official>
    <last_name>Gertjan Kaspers, MD, PhD</last_name>
    <role>Principal Investigator</role>
    <affiliation>Department of Pediatrics, VU University Medical Center Amsterdam De Boelelaan 1117, NL-1081 HV Amsterdam, The Netherlands</affiliation>
  </overall_official>
  <overall_official>
    <last_name>Birgitte Lausen, MD, PhD</last_name>
    <role>Principal Investigator</role>
    <affiliation>Dept of Pediatrics and Adolescent Medicine, Rigshospitalet, University of Copenhagen, Denmark</affiliation>
  </overall_official>
  <overall_official>
    <last_name>Josefine Palle, MD, PhD</last_name>
    <role>Principal Investigator</role>
    <affiliation>Dept of Woman´s and Children´s Health, Uppsala University, Uppsala, Sweden</affiliation>
  </overall_official>
  <overall_official>
    <last_name>Kadri Saks, MD, PhD</last_name>
    <role>Principal Investigator</role>
    <affiliation>Tallinn Children's Hospital, Dep. Hematology oncology, Tervise 28, Tallinn 13419, Estonia.</affiliation>
  </overall_official>
  <overall_official>
    <last_name>Bernward Zeller, MD, PhD</last_name>
    <role>Principal Investigator</role>
    <affiliation>Pediatric Dept, Women and Children's Division, Oslo University Hospital Rikshospitalet, Mailbox 4950 Nydalen, N-0424 Oslo, Norway</affiliation>
  </overall_official>
  <overall_contact>
    <last_name>Jonas Abrahamsson, MD, PhD</last_name>
    <phone>+46 707695159</phone>
    <email>jonas.abrahamsson@vgregion.se</email>
  </overall_contact>
  <overall_contact_backup>
    <last_name>Anna Schröder-Håkansson</last_name>
    <email>anna.schroder-hakansson@vgregion.se</email>
  </overall_contact_backup>
  <location>
    <facility>
      <name>HUDERF, L'Hôpital des Enfants Hématologie / Oncologie</name>
      <address>
        <city>Brussel</city>
        <zip>1020</zip>
        <country>Belgium</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Laurence Dedeken, MD, PhD</last_name>
      <phone>+32 2 4773311</phone>
      <email>laurence.dedeken@huderf.be</email>
    </contact>
  </location>
  <location>
    <facility>
      <name>UZ Brussel, Pediatrische Hemato-Oncologie F930</name>
      <address>
        <city>Brussel</city>
        <zip>1090</zip>
        <country>Belgium</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Jutte Van der Werff ten Bosch, MD, PhD</last_name>
      <phone>+32 2 4774111</phone>
      <email>JVDWerff@uzbrussel.be</email>
    </contact>
  </location>
  <location>
    <facility>
      <name>UCL, Cliniques Universitaires Saint-Luc</name>
      <address>
        <city>Brussel</city>
        <zip>1200</zip>
        <country>Belgium</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Sophie Dupont, MD, PhD</last_name>
      <phone>+32 2 7641111</phone>
      <email>sophie.dupont@uclouvain.be</email>
    </contact>
  </location>
  <location>
    <facility>
      <name>Ghent University Hospital, Children´s Hospital, Princess Elisabeth, Department of Pediatric Hematology-Oncology</name>
      <address>
        <city>Ghent</city>
        <zip>9000</zip>
        <country>Belgium</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Barbara de Moerloose, MD, PhD</last_name>
      <email>barbara.demoerloose@uzgent.be</email>
    </contact>
  </location>
  <location>
    <facility>
      <name>UZ Leuven, Kinder Hemato-Oncologie</name>
      <address>
        <city>Leuven</city>
        <zip>3000</zip>
        <country>Belgium</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Anne Uyttebroeck, MD, PhD</last_name>
      <phone>+32 16 33 22 11</phone>
      <email>anne.uyttebroeck@uzleuven.be</email>
    </contact>
  </location>
  <location>
    <facility>
      <name>CHR Citadelle</name>
      <address>
        <city>Liège</city>
        <country>Belgium</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Marie-Françoise Dresse, MD, PhD</last_name>
      <phone>+32 42238980</phone>
      <email>marie.francoise.dresse@chrcitadelle.be</email>
    </contact>
  </location>
  <location>
    <facility>
      <name>CHC Espérance</name>
      <address>
        <city>Montegnée</city>
        <country>Belgium</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Pierre Philippet, MD, PhD</last_name>
      <phone>+32 42249111</phone>
      <email>pierre.philippet@chc.be</email>
    </contact>
  </location>
  <location>
    <facility>
      <name>Department of Pediatrics, Aarhus University Hospital Skejby</name>
      <address>
        <city>Aarhus</city>
        <zip>8200</zip>
        <country>Denmark</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Henrik Hasle, MD, PhD</last_name>
      <email>hasle@dadlnet.dk</email>
    </contact>
  </location>
  <location>
    <facility>
      <name>Dept of Pediatrics and Adolescent Medicine, Rigshospitalet, University of Copenhagen</name>
      <address>
        <city>Copenhagen</city>
        <country>Denmark</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Birgitte Lausen, MD, PhD</last_name>
      <email>birgitte.lausen@rh.regionh.dk</email>
    </contact>
  </location>
  <location>
    <facility>
      <name>Tallinn Children's Hospital, Dep. Hematology oncology</name>
      <address>
        <city>Tallinn</city>
        <zip>13419</zip>
        <country>Estonia</country>
      </address>
    </facility>
    <status>Not yet recruiting</status>
    <contact>
      <last_name>Kadri Saks, MD, PhD</last_name>
      <email>kadri.saks@lastehaigla.ee</email>
    </contact>
  </location>
  <location>
    <facility>
      <name>Division of Hematology-Oncology and Stem Cell Transplantation, Children's Hospital, Helsinki University Central Hospital</name>
      <address>
        <city>Helsinki</city>
        <zip>00029</zip>
        <country>Finland</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Kirsi Jahnukainen, MD, PhD</last_name>
      <email>kirsi.jahnukainen@ki.se</email>
    </contact>
  </location>
  <location>
    <facility>
      <name>Department of Pediatrics, Kuopio University Hospital</name>
      <address>
        <city>Kuopio</city>
        <zip>70211</zip>
        <country>Finland</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Pekka Riikonen</last_name>
      <phone>+358 447172392</phone>
      <email>pekka.riikonen@kuh.fi</email>
    </contact>
    <investigator>
      <last_name>Pekka Riikonen</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>Department of Pediatrics, Oulu University Hospital</name>
      <address>
        <city>Oulu</city>
        <zip>90029</zip>
        <country>Finland</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Merja Möttönen</last_name>
      <phone>+358 83155251</phone>
      <email>merja.mottonen@ppshp.fi</email>
    </contact>
    <investigator>
      <last_name>Merja Möttönen</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>Department of Pediatrics, Tampere University Central Hospital</name>
      <address>
        <city>Tampere</city>
        <zip>33521</zip>
        <country>Finland</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Mikko Arola</last_name>
      <phone>+358 3 31164386</phone>
      <email>mikko.arola@pshp.fi</email>
    </contact>
    <investigator>
      <last_name>Mikko Arola</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>Department of Pediatrics, Turku University Central Hospital</name>
      <address>
        <city>Turku</city>
        <zip>20520</zip>
        <country>Finland</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Minna Koskenvuo, MD, PhD</last_name>
      <phone>+358 50 3624430</phone>
      <email>minna.koskenvuo@utu.fi</email>
    </contact>
    <investigator>
      <last_name>Minna Koskenvuo</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>Dept of Paediatrics &amp; Adolescent Medicine, Queen Mary Hospital, The University of Hong Kong</name>
      <address>
        <city>Hong Kong</city>
        <country>Hong Kong</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Shau-Yin Ha, MD, PhD</last_name>
      <email>syha@hku.hk</email>
    </contact>
  </location>
  <location>
    <facility>
      <name>Children´s Hospital, Landspitali University Hospital</name>
      <address>
        <city>Reykjavik</city>
        <country>Iceland</country>
      </address>
    </facility>
    <status>Not yet recruiting</status>
    <contact>
      <last_name>Olafur Jonsson, MD, PhD</last_name>
      <email>olafurgi@landspitali.is</email>
    </contact>
  </location>
  <location>
    <facility>
      <name>VU University Medical Center Department of Pediatric Oncology/Hematology</name>
      <address>
        <city>Amsterdam</city>
        <zip>1007</zip>
        <country>Netherlands</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Gertjan Kaspers, MD, PhD</last_name>
      <email>GJL.Kaspers@vumc.nl</email>
    </contact>
  </location>
  <location>
    <facility>
      <name>Emma Children's Hospital/ Amsterdam Medical Center Department of Pediatric Oncology</name>
      <address>
        <city>Amsterdam</city>
        <zip>1100 DD</zip>
        <country>Netherlands</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Huib Caron, MD, PhD</last_name>
      <email>h.n.caron@amc.uva.nl</email>
    </contact>
  </location>
  <location>
    <facility>
      <name>Department of Pediatric Oncology/Hematology Beatrix childrens hospital / University Medical Center Groningen</name>
      <address>
        <city>Groningen</city>
        <zip>9700 RB</zip>
        <country>Netherlands</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Eveline de Bont, MD, PhD</last_name>
      <email>e.de.bont@bkk.umcg.nl</email>
    </contact>
  </location>
  <location>
    <facility>
      <name>University Medical Center Nijmegen Department of Pediatric Oncology/Hematolog</name>
      <address>
        <city>Nijmegen</city>
        <zip>6500 HB</zip>
        <country>Netherlands</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Dunja te Loo, MD, PhD</last_name>
      <email>m.teloo@cukz.umcn.nl</email>
    </contact>
  </location>
  <location>
    <facility>
      <name>Erasmus MC - Sophia Childrens Hospital University Medical Center Rotterdam</name>
      <address>
        <city>Rotterdam</city>
        <zip>3000 CB</zip>
        <country>Netherlands</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Marry van den Heuvel-Eibrink, MD, PhD</last_name>
      <email>m.vandenheuvel@erasmusmc.nl</email>
    </contact>
  </location>
  <location>
    <facility>
      <name>Department of Pediatrics, Haukeland University Hospital, Bergen</name>
      <address>
        <city>Bergen</city>
        <zip>5021</zip>
        <country>Norway</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Dorota , Wojcik</last_name>
      <phone>+47 55 97 50 00</phone>
      <email>dorota.malgorzata.wojcik@helse-bergen.no</email>
    </contact>
    <investigator>
      <last_name>Dorota Wojcik</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>Pediatric Dept, Women and Children's Division, Oslo University Hospital Rikshospitalet</name>
      <address>
        <city>Oslo</city>
        <zip>N-0424</zip>
        <country>Norway</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Bernward Zeller, MD, PhD</last_name>
      <email>bernward.zeller@ous-hf.no</email>
    </contact>
  </location>
  <location>
    <facility>
      <name>Department of Pediatrics, University Hospital of North Norway, Tromsoe</name>
      <address>
        <city>Tromsoe</city>
        <zip>N-9038</zip>
        <country>Norway</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Trond Flaegstad</last_name>
      <phone>+47 91507766</phone>
      <email>Trond.Flaegstad@unn.no</email>
    </contact>
    <investigator>
      <last_name>Trond Flaegstad</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>Department of Cancer and Haemathology, St Olavs Hospital, Trondheim University Hospital</name>
      <address>
        <city>Trondheim</city>
        <zip>N-7006</zip>
        <country>Norway</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Svein Kolmannskog</last_name>
      <phone>+47 815 55 850</phone>
      <email>svein.kolmannskog@ntnu.no</email>
    </contact>
    <investigator>
      <last_name>Svein Kolmannskog</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>Queen Silvias Childrens and Adolescents Hospital</name>
      <address>
        <city>Gothenburg</city>
        <zip>41685</zip>
        <country>Sweden</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Jonas Abrahamsson, MD, PhD</last_name>
      <email>jonas.abrahamsson@vgregion.se</email>
    </contact>
    <investigator>
      <last_name>Jonas Abrahamsson</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>Dept of Pediatrics, Linköpings University Hospital</name>
      <address>
        <city>Linköping</city>
        <zip>58185</zip>
        <country>Sweden</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Mikael Behrendtz, MD, PhD</last_name>
    </contact>
    <investigator>
      <last_name>Mikael Behrendtz</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>Dept of Pediatrics, Skåne University Hospital</name>
      <address>
        <city>Lund</city>
        <zip>22241</zip>
        <country>Sweden</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Cornelis Pronk, MD, PhD</last_name>
      <email>kees-jan.pronk@med.lu.se</email>
    </contact>
  </location>
  <location>
    <facility>
      <name>Astrid Lindgrens Barnsjukhus, Karolinska University Hospital</name>
      <address>
        <city>Stockholm</city>
        <zip>17176</zip>
        <country>Sweden</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Karin Belander-Strålin, MD</last_name>
      <email>karin.belander-stralin@karolinska.se</email>
    </contact>
  </location>
  <location>
    <facility>
      <name>Dept of Pediatrics, Norrlands University Hospital</name>
      <address>
        <city>Umeå</city>
        <zip>90185</zip>
        <country>Sweden</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Ulrika Norén-Nyström, MD, PhD</last_name>
      <email>Ulrika.norennystrom@pediatri.umu.se</email>
    </contact>
  </location>
  <location>
    <facility>
      <name>Dept of Pediatrics, Akademiska barnsjukhuset</name>
      <address>
        <city>Uppsala</city>
        <zip>751 85</zip>
        <country>Sweden</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Josefine Palle, MD, PhD</last_name>
      <email>josefine.palle@akademiska.se</email>
    </contact>
  </location>
  <location_countries>
    <country>Belgium</country>
    <country>Denmark</country>
    <country>Estonia</country>
    <country>Finland</country>
    <country>Hong Kong</country>
    <country>Iceland</country>
    <country>Netherlands</country>
    <country>Norway</country>
    <country>Sweden</country>
  </location_countries>
  <verification_date>January 2017</verification_date>
  <!-- For several months we've had both old and new date name tags                             -->
  <!-- Now, the old date names have been dropped.                                               -->
  <!-- The new date name replacements are:                                                      -->
  <!--     OLD (gone)                                        NEW (in use)                       -->
  <!--   lastchanged_date                         becomes   last_update_submitted               -->
  <!--   firstreceived_date                       becomes   study_first_submitted               -->
  <!--   firstreceived_results_date               becomes   results_first_submitted             -->
  <!--   firstreceived_results_disposition_date   becomes   disposition_first_submitted         -->
  <study_first_submitted>April 6, 2013</study_first_submitted>
  <study_first_submitted_qc>April 9, 2013</study_first_submitted_qc>
  <study_first_posted type="Estimate">April 10, 2013</study_first_posted>
  <last_update_submitted>January 9, 2017</last_update_submitted>
  <last_update_submitted_qc>January 9, 2017</last_update_submitted_qc>
  <last_update_posted type="Estimate">January 10, 2017</last_update_posted>
  <responsible_party>
    <responsible_party_type>Sponsor</responsible_party_type>
  </responsible_party>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Leukemia</mesh_term>
    <mesh_term>Leukemia, Myeloid</mesh_term>
    <mesh_term>Leukemia, Myeloid, Acute</mesh_term>
  </condition_browse>
  <intervention_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Mitoxantrone</mesh_term>
    <mesh_term>Daunorubicin</mesh_term>
  </intervention_browse>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

